Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.

Hansen S, Hauge EM, Beck Jensen JE, Brixen K

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Apr 2013Cited by 112 (Europe PMC)

PMID23044908DOI10.1002/jbmr.1784PepBankPUB-23044908

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 increased radius cortical porosity from baseline.
In plain wordsIn women with osteoporosis, PTH increased cortical porosity at the radius compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius cortical porosity
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Porosity change
32%
radius
Source sentences
Summary
Anabolic therapy increased cortical porosity in radius (PTH 1-34 32 ± 37%, PTH 1-84 39 ± 32%, both p < 0.001) and tibia (PTH 1-34 13 ± 27%, PTH 1-84 15 ± 22%, both p < 0.001) with corresponding declines in cortical density.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490801
02HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 increased tibia cortical porosity from baseline.
In plain wordsIn women with osteoporosis, PTH increased cortical porosity at the tibia compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical porosity
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Porosity change
13%
tibia
Source sentences
Summary
Anabolic therapy increased cortical porosity in radius (PTH 1-34 32 ± 37%, PTH 1-84 39 ± 32%, both p < 0.001) and tibia (PTH 1-34 13 ± 27%, PTH 1-84 15 ± 22%, both p < 0.001) with corresponding declines in cortical density.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490802
03HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 decreased radius cortical density from baseline.
In plain wordsIn women with osteoporosis, PTH reduced cortical density at the radius compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius cortical density
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Anabolic therapy increased cortical porosity in radius (PTH 1-34 32 ± 37%, PTH 1-84 39 ± 32%, both p < 0.001) and tibia (PTH 1-34 13 ± 27%, PTH 1-84 15 ± 22%, both p < 0.001) with corresponding declines in cortical density.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490803
04HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 decreased tibia cortical density from baseline.
In plain wordsIn women with osteoporosis, PTH reduced cortical density at the tibia compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTibia cortical density
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Anabolic therapy increased cortical porosity in radius (PTH 1-34 32 ± 37%, PTH 1-84 39 ± 32%, both p < 0.001) and tibia (PTH 1-34 13 ± 27%, PTH 1-84 15 ± 22%, both p < 0.001) with corresponding declines in cortical density.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490804
05HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 increased radius cortical thickness from baseline.
In plain wordsIn women with osteoporosis, PTH increased cortical thickness at the radius compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius cortical thickness
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Thickness change
2%
radius
Source sentences
Summary
With PTH 1-34, increases in cortical thickness in radius (2.0 ± 3.8%, p < 0.05) and tibia (3.8 ± 10.4%, p < 0.01) were found.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490805
06HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 increased tibia cortical thickness from baseline.
In plain wordsIn women with osteoporosis, PTH increased cortical thickness at the tibia compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical thickness
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Thickness change
3.8%
tibia
Source sentences
Summary
With PTH 1-34, increases in cortical thickness in radius (2.0 ± 3.8%, p < 0.05) and tibia (3.8 ± 10.4%, p < 0.01) were found.
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490806
07HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 increased tibial trabecular number from baseline.
In plain wordsIn women with osteoporosis, PTH increased tibial trabecular number compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia trabecular number
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Trabecular number change
4.2%
tibia
Source sentences
Summary
Trabecular number increased in tibia with both PTH 1-34 (4.2 ± 7.1%, p < 0.05) and PTH 1-84 (5.3 ± 8.3%, p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490807
08HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 preserved but did not increase estimated radius strength.
In plain wordsIn women with osteoporosis, PTH preserved estimated radius strength without an increase from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius estimated strength
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
FE estimated bone strength was preserved, but not increased, with PTH 1-34 and zoledronic acid at both sites, whereas it decreased with PTH 1-84 in radius (-2.8 ± 5.8%, p < 0.05) and tibia (-3.9 ± 4.8%, p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490808
09HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, PTH 1‑34 preserved but did not increase estimated tibia strength.
In plain wordsIn women with osteoporosis, PTH preserved estimated tibia strength without an increase from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTibia estimated strength
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
FE estimated bone strength was preserved, but not increased, with PTH 1-34 and zoledronic acid at both sites, whereas it decreased with PTH 1-84 in radius (-2.8 ± 5.8%, p < 0.05) and tibia (-3.9 ± 4.8%, p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
in postmenopausal osteoporotic women treated with PTH 1-34 (20 µg sc daily, n = 18) or PTH 1-84 (100 µg sc daily, n = 20) for 18 months in an open-label, nonrandomized study.
Report a problemFND-2304490809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC